Guanhao Biotech Co Ltd (300238) — Net Asset Quality Index
Guanhao Biotech Co Ltd (300238) has a Net Asset Quality Index of 62.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥787.22 Million minus total liabilities of CN¥292.32 Million yields net assets of CN¥494.91 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check 300238 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Guanhao Biotech Co Ltd Net Asset Quality Index Over Time (2007–2025)
This chart shows how Guanhao Biotech Co Ltd's Net Asset Quality Index has evolved across 19 annual periods from 2007 to 2025. As of March 2026, the index stands at 62.9%, representing net assets of CN¥494.91 Million against total assets of CN¥787.22 Million CNY. See Guanhao Biotech Co Ltd (300238) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Guanhao Biotech Co Ltd (2007–2025)
The table below presents the year-by-year Net Asset Quality Index for Guanhao Biotech Co Ltd from 2007 to 2025, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see market value of Guanhao Biotech Co Ltd.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 62.7% | CN¥506.03 Million | CN¥806.53 Million | CN¥300.50 Million | ▲ +0.8 pp |
| 2024 | 62.0% | CN¥467.59 Million | CN¥754.40 Million | CN¥286.81 Million | ▼ -5.3 pp |
| 2023 | 67.2% | CN¥456.26 Million | CN¥678.59 Million | CN¥222.33 Million | ▲ +2.9 pp |
| 2022 | 64.3% | CN¥430.88 Million | CN¥670.21 Million | CN¥239.33 Million | ▼ -3.8 pp |
| 2021 | 68.1% | CN¥748.16 Million | CN¥1.10 Billion | CN¥350.58 Million | ▲ +4.9 pp |
| 2020 | 63.2% | CN¥716.66 Million | CN¥1.13 Billion | CN¥418.07 Million | ▲ +1.9 pp |
| 2019 | 61.3% | CN¥704.14 Million | CN¥1.15 Billion | CN¥445.21 Million | ▼ -9.2 pp |
| 2018 | 70.5% | CN¥1.16 Billion | CN¥1.64 Billion | CN¥483.57 Million | ▼ -0.1 pp |
| 2017 | 70.6% | CN¥1.21 Billion | CN¥1.72 Billion | CN¥505.25 Million | ▼ -15.7 pp |
| 2016 | 86.3% | CN¥1.46 Billion | CN¥1.69 Billion | CN¥230.93 Million | ▲ +9.4 pp |
| 2015 | 76.9% | CN¥620.62 Million | CN¥807.02 Million | CN¥186.41 Million | ▼ -8.9 pp |
| 2014 | 85.8% | CN¥531.61 Million | CN¥619.54 Million | CN¥87.92 Million | ▼ -1.2 pp |
| 2013 | 87.0% | CN¥498.16 Million | CN¥572.52 Million | CN¥74.36 Million | ▲ +3.2 pp |
| 2012 | 83.8% | CN¥454.11 Million | CN¥541.99 Million | CN¥87.88 Million | ▼ -3.5 pp |
| 2011 | 87.2% | CN¥432.79 Million | CN¥496.06 Million | CN¥63.27 Million | ▲ +25.8 pp |
| 2010 | 61.4% | CN¥144.99 Million | CN¥236.02 Million | CN¥91.03 Million | ▼ -1.5 pp |
| 2009 | 62.9% | CN¥76.95 Million | CN¥122.30 Million | CN¥45.34 Million | ▲ +3.1 pp |
| 2008 | 59.9% | CN¥37.01 Million | CN¥61.82 Million | CN¥24.81 Million | ▲ +9.1 pp |
| 2007 | 50.8% | CN¥20.67 Million | CN¥40.70 Million | CN¥20.03 Million | — |